<DOC>
	<DOCNO>NCT01999569</DOCNO>
	<brief_summary>The purpose study establish sustain estrogen level drive force LH surge , thereby necessary ovulation occur . We predict reduce level circulate estrogen , letrozole , aromatase inhibitor , inhibit ovulation occur .</brief_summary>
	<brief_title>The Role Estrogen Luteinizing Hormone Surge Ovulation</brief_title>
	<detailed_description>Sine common understand ovulation natural cycle suggest sustain , elevate estradiol level require trigger LH surge , administration letrozole throughout cycle lower estradiol level prevent LH surge occur . In study , seek determine LH surge , ovulation luteinization occur spite low estradiol level daily administration letrozole group normal ovulatory volunteer prospective study . After IRB approval inform consent obtain , ten willing volunteer meet inclusion criterion ( hormonal contraception within 3 month , regular menstrual cycle 26 - 30 day , normal thyroid function normal prolactin , pregnancy currently within 3 month ) monitor one month without treatment evaluation normal ovulation . Natural control cycle The subject use home urine LH test ( Clearblue® Easy , SPD Swiss Precision Diagnostics , Switzerland ) day 10-18 monitor LH surge initial natural cycle letrozole cycle . Blood drawn every day start day 12 cycle day 22 measure estradiol progesterone level , follicular development monitor use transvaginal ultrasound cycle day 12-14 . Letrozole cycle In next cycle , ten subject administer oral letrozole 5 mg daily ( Femara® , Novartis Pharmaceuticals Corporation , East Hanover , NJ ) start cycle day 1-3 continue completion study ( cycle day 22 ) . Once , serum estradiol progesterone level measure every day day 12-22 . The development ovarian follicle monitor transvaginal ultrasound cycle day 12-14 , LH surge monitor home urine ovulation test day 10-18 . Table 1 illustrates protocols natural control cycle letrozole study cycle . The primary outcome , assessment ovulation letrozole cycle , determine presence absence progesterone elevation ( &gt; 1.5 ng/mL ) presence absence positive urinary LH test . The bioequivalence evaluation two cycle ( letrozole administration ) base pharmacokinetic parameter area serum concentration-time curve ( AUC ) , peak serum concentration ( Cmax ) time peak serum concentration ( Tmax ) . Cmax Tmax determine visual inspection volunteer 's serum concentration-time curve estradiol progesterone . AUC calculate linear trapezoidal method day 12 day 22 initial natural cycle letrozole cycle . Paired t-tests , Wilcoxon Signed Rank test non-normally distribute , use evaluate statistical significance mean value pharmacokinetic parameter . The McNemar test use assess difference LH surge follicular development letrozole administration . A standard statistical significance ( alpha ) 0.05 used case . The SAS System ( SAS Institute , Cary , NC ) use analysis .</detailed_description>
	<mesh_term>Ovarian Cysts</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patient regular menstrual cycle 2630 day Ages 1840 Patient must sexually active study period , must use reliable form nonhormonal birth control include tubal ligation vasectomy , nonhormonal intrauterine contraceptive device ( IUD ) , condoms spermicide . Willing participate study available monitoring visit . IRB consent Patient must NOT use hormonal contraception three month less prior study . Irregular menstrual cycle ( &lt; 26 day &gt; 30 day within last 6 month . Untreated thyroid dysfunction hyperprolactinemia Pregnancy ( current within 3 month ) breastfeed Allergy contraindication letrozole</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>